Press coverage about Omeros (NASDAQ:OMER) has trended positive recently, Alpha One Sentiment Analysis reports. The research firm, a service of Accern, scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Omeros earned a daily sentiment score of 0.29 on Alpha One’s scale. Alpha One also assigned media coverage about the biopharmaceutical company an impact score of 48 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have effected AlphaOne Sentiment’s analysis:
- Man avoids paying for slap up £375 seafood feast in quite remarkable way (mirror.co.uk)
- Aspiring rapper charged with eating $669 of seafood before dashing into sea says restaurant should apologise to him (i.stuff.co.nz)
- Rapper’s insane $600 dine and dash excuse (spy.nzherald.co.nz)
- This Rapper Jumped Into The Sea To Avoid Paying A £360 Bill (esquire.co.uk)
- Australian rapper flees into sea after racking up huge bill at seafood restaurant, court told (standard.co.uk)
Shares of Omeros (NASDAQ:OMER) traded down 3.38% on Thursday, reaching $15.42. The company had a trading volume of 585,916 shares. The company has a 50 day moving average of $13.06 and a 200-day moving average of $10.93. The company’s market capitalization is $675.74 million. Omeros has a 52 week low of $7.20 and a 52 week high of $17.19.
OMER has been the subject of a number of analyst reports. Zacks Investment Research cut Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, January 4th. Maxim Group restated a “buy” rating on shares of Omeros in a research note on Wednesday, March 1st. FBR & Co restated a “buy” rating on shares of Omeros in a research note on Thursday, March 2nd. Wedbush restated an “outperform” rating and set a $47.00 price objective on shares of Omeros in a research note on Wednesday, February 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective (down from $24.00) on shares of Omeros in a research note on Friday, March 17th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $33.38.
ILLEGAL ACTIVITY NOTICE: “Omeros (OMER) Receiving Favorable Media Coverage, Report Finds” was published by sleekmoney and is the sole property of of sleekmoney. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at http://sleekmoney.com/omeros-omer-receiving-favorable-media-coverage-report-finds/1739657.html.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/omeros-omer-receiving-favorable-media-coverage-report-finds/1739657.html
Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with MarketBeat.com's FREE daily email newsletter.